Mukul Agrawal Portfolio Vs Ashish Kacholia Portfolio

Mukul Agrawal’s portfolio, valued at ₹7,283.1 crore, emphasizes diversified growth with significant stakes in BSE and Neuland Laboratories. Ashish Kacholia’s portfolio, worth ₹3,215.1 crore, focuses on high-growth stocks like Beta Drugs, reflecting distinct investment philosophies. Both portfolios highlight unique strategies suited for market resilience.

Who is Mukul Agrawal?

Mukul Agrawal is a prominent Indian investor known for his diversified portfolio across multiple sectors. With a net worth of ₹7,283.1 crore, he is recognized as a leading figure in the Indian stock market, consistently identifying high-potential growth opportunities. His investments reflect strategic foresight and strong financial acumen.

Born in India, Mukul Agrawal hails from a business-oriented family that inspired his early interest in investments. His disciplined approach to stock market trading has earned him recognition and accolades, ranking him among India’s top investors by net worth. He is celebrated for his value-oriented investment style.

Often called an ace investor, Mukul Agrawal’s investment philosophy combines a balance of risk and reward. With his growing net worth and consistent stock performance, he continues to be a major influence in Indian markets. His strategies inspire both seasoned and budding investors.

Who is Ashish Kacholia?

Ashish Kacholia, dubbed the “Big Whale” of Indian stock markets, is a celebrated investor with a diverse portfolio worth ₹3,215.1 crore. Known for his strategic picks, he avoids media attention and lets his investments speak for themselves. His growth-focused strategy sets him apart.

Born in Mumbai, Ashish Kacholia comes from a finance-oriented background. He founded Lucky Securities in 1995 and co-founded Hungama Digital in 1999, establishing himself as a key player in the financial world. His portfolio reflects expertise in identifying multi-baggers.

With the nickname “Big Whale,” Kacholia’s net worth and consistent stock performance rank him among India’s top investors. His focus on high-growth sectors like manufacturing and healthcare solidifies his reputation in Indian markets. He remains an inspiration for disciplined investing.

What Is The Qualification of Mukul Agrawal?

Mukul Agrawal’s qualifications lie in his extensive experience and success in stock market investments. As a full-time investor, he leverages his deep market insights to build a diverse portfolio and achieve consistent returns. His professional journey showcases a mastery of financial strategies.

Agrawal’s education and professional journey emphasize practical experience in finance and investments. His ability to identify multi-bagger opportunities showcases his financial acumen, placing him among India’s top investors. He has consistently emphasized value and stability in his holdings.

His qualifications as an investor stem from years of expertise in managing diverse portfolios. By focusing on long-term growth strategies, Agrawal has carved a niche in the Indian financial markets. His disciplined approach continues to inspire investor confidence.

What Is The Qualification of Ashish Kacholia?

Ashish Kacholia’s qualifications are rooted in his financial expertise and market experience. He honoured his skills through roles at Prime Securities and Edelweiss before establishing his broking firm, Lucky Securities, in 1999. His education complements his practical success in investments.

His educational background complements his practical expertise in identifying undervalued stocks and creating multi-bagger opportunities. This combination has enabled him to maintain a consistent record of successful investments. He is recognized as a pioneer in identifying scalable businesses.

As a seasoned investor, Kacholia’s qualifications emphasize experience-driven learning. His diversified portfolio across sectors underscores his ability to leverage financial insights for consistent growth. His strategies are benchmarks for market adaptability and resilience.

Investing Strategies – Mukul Agrawal vs. Ashish Kacholia

The main difference between Mukul Agrawal and Ashish Kacholia lies in their focus. Mukul Agrawal leans toward value-based midcap investments, emphasizing turnaround stories, while Ashish Kacholia prioritizes high-growth opportunities in small-cap stocks, ensuring portfolio diversification across industries and maximizing long-term returns through distinct investment approaches.

Criteria	Mukul Agrawal	Ashish Kacholia
Focus	Midcap investments with value-based turnaround stories.	High-growth small-cap opportunities.
Investment Approach	Emphasizes undervalued stocks with potential for recovery.	Prioritizes stocks with consistent growth and innovation.
Portfolio Diversification	Moderate diversification across midcap and large sectors.	Highly diversified portfolio across multiple industries.
Risk Tolerance	Moderate risk with a focus on consistent returns.	High risk to capitalize on growth potential in small caps.
Key Strength	Identifying undervalued businesses during market corrections.	Spotting emerging industry leaders with growth trajectories.

Mukul Agrawal Portfolio Vs Ashish Kacholia Portfolio Holdings

Mukul Agrawal’s portfolio, worth ₹7,283.1 crore, emphasizes financial and industrial sectors with stocks like BSE and Neuland Laboratories. Ashish Kacholia’s ₹3,215.1 crore portfolio focuses on manufacturing and healthcare, featuring Beta Drugs and Safari Industries. Both portfolios showcase strategic diversification and long-term growth potential.

Investor	Stock Name	Holding Value (₹ Crore)	Quantity Held	Stake (%)
Mukul Agrawal	BSE	1,068.00	20,00,000.00	1.50
Mukul Agrawal	Neuland Laboratories	551.00	4,00,000.00	3.10
Ashish Kacholia	Beta Drugs	247.30	12,03,644.00	12.50
Ashish Kacholia	Safari Industries	238.70	9,00,000.00	1.80

Performance of Mukul Agrawal Portfolio Over 3 Years

Mukul Agrawal’s portfolio has demonstrated strong growth over three years, with standout stocks like BSE and Neuland Laboratories. His diversified approach across financial and industrial sectors has ensured consistent returns and balanced portfolio performance.

Historical performance indicates resilience and scalability, with BSE Ltd. achieving a 3-year CAGR of 25%, growing a ₹350 crore investment to ₹683 crore, and Neuland Laboratories delivering a CAGR of 30%, with ₹200 crore appreciating to ₹370 crore. Agrawal’s focus on diversification has minimized risks while maximizing growth opportunities, cementing his position among top investors.

Agrawal’s ability to identify value stocks with long-term growth potential has made his portfolio a model for consistency. His focus on scalability ensures his investments remain relevant and robust in evolving markets.

Performance of Ashish Kacholia Portfolio Over 3 Years

Ashish Kacholia’s portfolio has delivered robust performance over the last three years, with an annualized return of approximately 24%. Stocks like Beta Drugs (3-year CAGR: 28%) and Safari Industries (3-year CAGR: 30%) achieved exceptional growth, reflecting his ability to identify multibagger opportunities early.

Data shows consistent returns across sectors, particularly in manufacturing and hospitality. For instance, ₹1 crore invested in Beta Drugs three years ago would now be worth approximately ₹2.14 crore, while Safari Industries would have grown to ₹2.19 crore. His net worth is currently ₹3,215.1 crore, underscoring his success in identifying high-growth stocks and maintaining a diversified portfolio.

Kacholia’s portfolio performance reaffirms his reputation as a top-tier investor. His focus on scalable businesses with high-growth potential has positioned his portfolio for long-term success, solidifying his standing as one of India’s leading investors.

How to Invest in Mukul Agrawal and Ashish Kacholia Portfolio Stocks?

Investing in Mukul Agrawal and Ashish Kacholia’s stocks requires identifying their key holdings and tracking performance metrics. Using Alice Blue, investors can efficiently access these portfolios and manage investments for long-term gains. Their stocks offer significant growth opportunities.

Research their top holdings like BSE and Beta Drugs, analyzing financial health and market trends. Alice Blue simplifies trading with insights, cost-effective solutions and portfolio tracking tools to align with their strategies. Diversification remains a key principle.

Investors must focus on diversification and patience to replicate their success. Alice Blue provides the tools to execute investments in these ace investors’ portfolios effectively. Understanding market dynamics is essential for maximizing returns.

Mukul Agrawal Portfolio Vs Ashish Kacholia Portfolio : Conclusion

Mukul Agrawal (Ace Investor 1) predominantly allocates to financial and industrial sectors, with major investments in BSE. He consistently increases his stake in high-potential businesses like Neuland Laboratories, showcasing a balanced approach to long-term growth and stability.

Ashish Kacholia (Ace Investor 2) focuses on manufacturing and healthcare, significantly investing in Beta Drugs. He emphasizes high-growth stocks across diversified sectors, frequently increasing stakes in companies with scalable operations. Both portfolios underline their distinct strategies for wealth creation and market resilience.

Mukul Agrawal Portfolio Vs Ashish Kacholia Portfolio : FAQ

What is Mukul Agrawal’s Best Portfolio?

Mukul Agrawal’s best portfolio includes stocks like BSE and Neuland Laboratories, reflecting a strategic focus on the financial and industrial sectors. These stocks consistently deliver strong returns, showcasing his expertise in identifying high-potential investments. His diversified approach ensures sustained portfolio growth.

What is Ashish Kacholia’s Best Portfolio?

Ashish Kacholia’s best portfolio features stocks like Beta Drugs and Safari Industries, emphasizing high-growth sectors like manufacturing and healthcare. These investments highlight his ability to identify multi-bagger opportunities with significant long-term potential. His strategic choices reflect market foresight.

What Is The Net Worth Of Mukul Agrawal?

Mukul Agrawal’s net worth exceeds ₹7,283.1 crore, as per the latest filings. His diversified portfolio and consistent stock performance have established him among India’s leading investors. His wealth reflects his disciplined and strategic investment style.

What Is The Net Worth Of Ashish Kacholia?

Ashish Kacholia’s net worth stands at ₹3,215.1 crore, reflecting his success in high-growth investments across diverse sectors. His strategic portfolio makes him a prominent name in Indian markets. His approach balances innovation with stability.

What Is The Rank Of Mukul Agrawal In India?

Mukul Agrawal ranks among India’s top individual investors, with a portfolio valued at approximately ₹7,283.1 crore, reflecting a 46% increase from ₹4,741 crore in December 202 This substantial growth underscores his strategic investment acumen in the Indian stock market.

What Is The Rank Of Ashish Kacholia In India?

Ashish Kacholia is ranked among India’s top 30 investors, recognized for his expertise in identifying high-growth potential midcap and small-cap stocks. His portfolio is highly regarded in the stock market, showcasing consistent performance and diversification across various emerging sectors.

Which Sector Did Mukul Agrawal Majorly Hold Stake In?

Mukul Agrawal primarily holds stakes in the financial and industrial sectors. Key investments like BSE and Neuland Laboratories reflect his strategic focus on stable and scalable businesses. His sectoral focus ensures a balanced portfolio.

Which Sector Did Ashish Kacholia Majorly Hold Stake In?

Ashish Kacholia majorly holds stakes in the manufacturing and healthcare sectors. Stocks like Beta Drugs underline his focus on high-growth companies with significant market potential. His strategic focus aligns with scalable and resilient industries.

How to Invest in Mukul Agrawal and Ashish Kacholia’s Stocks?

Investors can use Alice Blue to invest in Mukul Agrawal and Ashish Kacholia’s stocks. Research their top holdings, track performance and adopt a long-term strategy for consistent returns. Their portfolios offer lessons in market adaptability and disciplined investing.

Disclaimer: The above article is written for educational purposes and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.